Natural Alternatives International Inc. (NAII)
NAII trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/787253/000143774926031343/0001437749-26-031343-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | NAII on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000787253 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $142.5M |
| Net income | -$20.7M |
| Operating income | -$18.8M |
| Net margin | -14.5% |
| Operating margin | -13.2% |
| Revenue growth | +9.7% |
| Cash | $7.4M |
| Total assets | $126.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management identified the following conditions that raised substantial doubt about the Company's ability to continue as a going concern: Net losses and negative operating cash flows;" | 10-Q 2026-11-13 |
| Cash and burn | $7.4M cash; operating cash flow -$2.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 6,259,181 (2026-11-13); 6,176,778 a year earlier; 6,088,813 three years earlier. | Cover page 2026-11-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-09-28 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-05-18 |
| Insider trades, 12 months | Bought $27K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | $34.5M | -$13.5M | -$1.1M | $7.4M | $733K | $142.5M | 10-K 2026-09-28 |
| Q3 2026 2026-03-31 | $35.5M | -$4.3M | $2.5M | $9.2M | $312K | $141.9M | 10-Q 2026-05-19 |
| Q2 2026 2025-12-31 | $34.8M | -$2.6M | -$6.3M | $3.8M | $310K | $135.2M | 10-Q 2026-02-13 |
| Q1 2026 2025-09-30 | $37.7M | -$291K | -$4.0M | $7.7M | $308K | $134.4M | 10-Q 2025-11-12 |
| Q4 2025 2025-06-30 | $33.9M | -$7.2M | $3.3M | $12.3M | $305K | $129.9M | 10-K 2026-09-28 |
| Q3 2025 2025-03-31 | $28.8M | -$2.2M | $6.0M | $10.6M | $303K | $125.5M | 10-Q 2026-05-19 |
| Q2 2025 2024-12-31 | $34.1M | -$2.2M | $37K | $8.7M | $301K | $121.9M | 10-Q 2026-02-13 |
| Q1 2025 2024-09-30 | $33.1M | -$2.0M | -$3.4M | $10.2M | $298K | $113.0M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2006-03-03 |
| Latest annual report FORM 10-K | 10-K | 2026-09-28 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-13 |
| Latest current report FORM 8-K | 8-K | 2026-05-01 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-10-23 |
Source: SEC EDGAR submissions feed, 778 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.6% |
| 1 month | -15.7% |
| 3 months | -55.3% |
| Year to date | -72.9% |
| 1 year | -71.1% |
| From 52-week high | -79.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKAN | Akanda Corp. Common Shares | $2.21 | +62.50% | $5.3M |
| MTEX | Mannatech Incorporated | $3.76 | -40.32% | $7.3M |
| BON | Bon Natural Life Limited | $1.09 | -0.91% | $8.9M |
| BTMD | Biote Corp. | $0.9603 | -9.83% | $34.5M |
| IMCC | IM Cannabis Corp. Common Shares | $0.4950 | -12.76% | $913K |
| FTLF | FitLife Brands Inc. | $6.83 | -19.46% | $64.1M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier